SecBot SecBot
3 ·Filed Nov 4, 2026

XERS

Xeris Biopharma Holdings, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed12d 10h ago SEC0001867096-26-000103
Form 3: initial insider ownership statement
Actionable Insight • Neutral

Monitor future Form 4 filings for any open-market purchases or grants that would signal insider conviction. No immediate read-through from this initial filing.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$13.08
T+0 close · Nov 4, 2026 · via day close
Latest settled
+27.29%
T+5 · $16.65 · next T+20 in 17d
Vs SPY
+24.00%
α at T+5
Latest observation
+26.30%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $13.08entry
  2. T+1 · 11d ago +16.21%α +15.90% · $15.20
  3. T+5 · 5d ago +27.29%α +24.00% · $16.65
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Menassie Taddese filed a Form 3 initial statement of beneficial ownership and a related power of attorney, reporting zero beneficial ownership of Xeris Biopharma Holdings, Inc. securities as of the event date. This is a routine filing by a new director with no securities held, carrying no material financial impact.

Key Facts

  • Menassie Taddese filed a Form 3 initial statement of beneficial ownership on 2026-11-04, with a period of report of 2026-11-02.
  • The filing reports zero beneficial ownership: 0 shares, 0 derivative securities.
  • A power of attorney (Exhibit 24) was filed, appointing John Shannon, Beth Hecht, and Steve Pieper as attorneys-in-fact for Section 16 filings.
  • Taddese's business address is listed as Xeris Biopharma's Chicago headquarters, and his mailing address is in Canonsburg, PA.

Financial Impact

No financial impact; zero shares reported.

Risk Factors

  • No risks identified from this routine filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0001867096-26-000103
Document: 0001867096-26-000103-index-headers.html0001867096-26-000103
Document: 0001867096-26-000103-index.html0001867096-26-000103
Document: 0001867096-26-000103.txt0001867096-26-000103

Track record

25 reports on XERS

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +45.52% at T+60 after the Aug 6, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $15.86 Now $16.70 +5.30% settles Dec 8
  2. Nov 5, 202611d ago 144 Neutral 2/10 Entry $15.20 Now $16.70 +9.87% settles Dec 7
  3. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
  4. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
  5. Nov 4, 202612d ago 3 Neutral 2/10 Viewing Entry $13.08 Now $16.70 +27.68% settles Dec 4
  6. Nov 2, 202614d ago 144 Neutral 2/10 Entry $10.35 Now $16.70 +61.35% settles Dec 2
  7. Nov 2, 202614d ago 8-K Neutral 2/10 Entry $10.17 Now $16.70 +64.21% settles Dec 1
  8. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $10.71 Now $16.70 +55.93% settles Nov 30
  9. Oct 14, 20264w ago 8-K Neutral 3/10 Entry $9.77 to $16.52 Now $16.70 +70.93% ▲ +69.09% +70.36% vs SPY
  10. Oct 2, 20266w ago Insider Cluster Neutral 3/10 Entry $10.13 to $10.71 Now $16.70 +64.86% ▲ +5.73% +8.19% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 5h 48m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026